TWI430807B - Gastrointestinal composition for synergistically increasing peristalsis of digestive tract - Google Patents

Description

Gastrointestinal composition that synergistically increases the activity of digestive tract movement

The present invention relates to a gastrointestinal drug composition which is substantially enhanced in the effect of vitamin U (MMSC) and atractylodes.

Generally, the gastrointestinal drug system exhibits the effects of alleviating symptoms such as overeating, heartburn, bloating, stomach pain, nausea, vomiting, etc., and is widely used in order to maintain the health of the gastrointestinal tract or restore its health. For digestive medicine, stomach medicine, antacid medicine, compound gastrointestinal medicine, gastrointestinal analgesic and antispasmodic drugs.

Vitamin U (MMSC) has the effect of repairing a worsening gastric mucosa and is widely used as a component of gastrointestinal drugs, particularly compound gastrointestinal drugs. Furthermore, Atractylodes lancea De Candolle or the root of Atractylodes chinensis Koidzumi has been considered herbal medicine since ancient times and can be used mainly as a stomach digestive or antidiarrheal intestine medicine. Etc. (Non-Patent Document 1). However, the pharmaceutical compositions of the two, especially the gastrointestinal tract, have not existed until now.

(Non-Patent Document 1) The 14th revision of the Japanese Pharmacy Bureau's Fang Jieshu, 2001, D-674 to 677 pages

It is an object of the present invention to provide a novel gastrointestinal drug composition which is significantly more effective than conventional gastrointestinal drugs.

The inventors used a combination of vitamin U (MMSC), which is known as a gastric mucosa repairing agent, and a known activating technique for digestive tract movement, which is known as a stomach digestive or antidiarrheal intestine, and found that it has a significant effect on the movement of the digestive tract. As a fullness, vomiting, nausea or even vomiting, or chest pressure, bloating, indigestion, stomach. The effect of the gastrointestinal drug such as the abdomen swelling or the relief of loss of appetite is drastically increased, and the present invention has been completed.

That is, the present invention provides a composition for gastrointestinal medicine containing MMSC and Atractylodes lancea. In addition, the present invention relates to alleviating satiety, vomiting, nausea or even vomiting, or chest compression, bloating, indigestion, and stomach. Abdominal swelling or even loss of appetite contains MMSC and Atractylodes gastrointestinal composition.

The gastrointestinal drug composition of the present invention, which can not be obtained by using MMSC or Atractylodes alone, can synergistically increase the activity of digestive tract movement, MMSC has fullness, vomiting, nausea or even vomiting inhibition, or chest Pressure, bloating, indigestion, stomach. The effects of abdominal swelling or loss of appetite are significantly improved.

MMSC is a pharmaceutical product that began to be sold in 1959, mainly as a gastric mucosal repair agent, or as a liver function improvement for chronic liver disease. However, there is a significant effect on the digestive tract movement by combining the use of MMSC with Atractylodes, and the result is a suppressive effect of satiety, vomiting, nausea or even vomiting, or chest compression, bloating, indigestion, and stomach. The mitigation effect of abdominal swelling or loss of appetite is not inferred and reported until the case of significantly increased MMSC alone.

In addition, although the function of the movement of the digestive tract into the atractylodes of Atractylodes is known (Non-Patent Document 1), it is synergistically enhanced by the use of MMSC in combination with it, and as a result, it is a gastrointestinal composition containing MMSC and Atractylodes The effect is synergistically increased, and there is no inference and report so far.

The present invention provides a gastrointestinal drug composition which has synergistically enhanced effects which cannot be achieved when used alone, by the combination of MMSC and Atractylodes, which have not been used in the past.

The gastrointestinal drug composition of the present invention, as shown in the following examples, has a digestive tract movement activation function expressed by intestinal tube delivery rate. The effect is more remarkable than the sum of the effects confirmed when MMSC and Atractylodes are used alone, and synergistically activates the movement of the digestive tract.

The present invention is not limited by the following inferences, and the present invention is based on the synergistic activation of the digestive tract movement, the fullness of the intestinal tube contents, vomiting, nausea or even vomiting, chest compression, bloating caused by the retention of intestinal contents. Indigestion, stomach. Symptoms such as abdominal swelling or loss of appetite, especially the symptoms of palliative remission caused by excessive drinking or overeating, were significantly improved compared to MMSC or Atractylodes alone. In addition, due to the synergistic activation of the digestive tract movement, the internal retention of the intestinal tract is relieved, and the digestive promoting effect can be more strongly promoted.

The MMSC used in the present invention can be used as a product commercially available from Yonezawa Hama Pharmaceutical Co., Ltd., or can be synthesized and used in accordance with the method described in Japanese Patent Publication No. Sho 36-13209. Alternatively, as for atractylodes, it is also possible to use it as a widely used herbal ingredient.

The ratio of MMSC to Atractylodes and the synergistic effect of the two, the weight ratio of MMSC: Atractylodes (original herbal conversion) 9: 8 to 3: 500, especially 1: 2 to 1: 5 In particular, it is possible to strongly exert synergistic effects due to the combination. Furthermore, the blending amount of the composition of MMSC and Atractylodes can also be used as the range of the gastrointestinal drug composition arbitrarily adjusted, and each of them is determined to satisfy the aforementioned blending ratio.

In addition, the gastrointestinal drug composition of the present invention may be used in addition to MMSC and Atractylodes sinensis, or may contain a pharmaceutically acceptable carrier or other pharmaceutical ingredients, excipients, binding agents, disintegrating agents, smoothing agents, coloring agents, A flavoring agent or the like is used as a pharmaceutical composition.

Examples of the excipient include lactose, starch, crystalline cellulose, sucrose, mannitol, and light anhydrous citric acid. Examples of the binding agent include hydroxypropylmethylcellulose, hydroxypropylcellulose, gelatin, α-starch, polyvinyltetrahydropyrrolidone, polyvinyl alcohol, and pupa polysaccharide. Examples of the disintegrator include carboxymethylcellulose, carboxymethylcellulose calcium, interactive sodium carboxymethylcellulose, cross-vinyl ketone, corn starch, and low-substituted hydroxypropylcellulose. Examples of the smoothing agent include magnesium stearate and talc. Examples of the colorant include tar dye, ruthenium trioxide, and the like. Examples of the flavoring agent include stevia, aspartame, and flavor.

The gastrointestinal drug composition of the present invention may be used in the form of a powder, a granule, a troche, a chewable tablet, a filming agent, a sugar-coated tablet, a drink, a soft capsule, a hard capsule, or a jelly, depending on the purpose. In particular, it is preferably used as a powder, a granule, a tablet, or a film-coating agent.

In addition, the dosage of the gastrointestinal composition containing MMSC and Atractylodes to humans depends on factors such as the dosage form, the degree of the disease, the age of the patient, etc., and the adult MMSC is usually administered with a daily dose of about 30 to 3000 mg, especially daily. A dose of 100 to 225 mg, in combination with the required dosage, can determine the amount of atractylodes.

Hereinafter, the present invention is described in detail based on the examples, but the present invention is not limited thereto.

[Example 1]

The ddY male rats that were fasted for 5 weeks from the 1st day before the experiment were orally administered with a suspension of 0.5% methylcellulose (hereinafter referred to as MC) of vitamin U (1000 mg/kg, hereinafter referred to as M), Atractylodes sinensis L. extract (300 mg/kg, original herbal amount 3000 mg/kg, hereinafter referred to as S) and its mixture (hereinafter referred to as M+S), and oral administration of activated carbon powder after 15 minutes Suspension, further, 30 minutes later, the animals were sacrificed by cervical dislocation and the intestines from the pylorus to the ileocecal area were removed. The intestinal tube delivery function of the test substance is divided by the moving distance of the pyloric carbon powder by the full length of the intestinal tube, and the intestinal tube delivery rate is expressed.

The test results are shown in Table 1.

M: Vitamin US: Atractylodes sinensis extract S1) The proportion of intestinal tube delivery rate when the intestinal tube delivery rate of the control group was 1.

The intestinal tube delivery rate was 48.5% in the control group administered to MC, 69.0% in the M group, 53.0% in the S group, and 76.2% in the M+S group. When the intestinal tube delivery rate of the control group was 1, the ratio of intestinal delivery rate in the M+S group was 1.57. It is greater than the product ratio of 1.55 (1.42 × 1.09) and the synergistic effect. Thus, the present invention promotes the kinetic function of the digestive tract, and as a result, it is apparent that it is very useful as a suppressing effect of satiety, vomiting, nausea or even vomiting, or chest compression, bloating, indigestion, and stomach. A gastrointestinal drug composition that significantly enhances the swelling of the abdomen or the loss of appetite.

[Embodiment 2]

Using Lactose as an excipient, granules containing MMSC were granulated according to a general wet granulation method, and compression-molded according to a general method to produce an A tablet containing 25 mg of MMSC per one tablet. Further, a B tablet containing 25 mg of MMSC and 12 mg of atractylodes (original herbal conversion) per one tablet was produced in the same manner.

For volunteers aged 20 to 59 who have a certain degree of abdominal discomfort in their stomachs, they were randomly sampled and divided into two groups of 5, and A tablets were given to group A, and B tablets were given to group B. On the 3rd, 2 tablets were taken after each meal. Before, during and after the treatment, the symptoms of restless troubles were answered in the form of a questionnaire. The results are shown in Table 2.

As clearly shown in Table 2, the group B of the gastrointestinal drug composition of the present invention was confirmed to have a significant improvement effect on the abdominal discomfort.

Claims (5)

A gastrointestinal drug composition for synergistically increasing the activity of digestive tract movement, comprising methylmethionine sulfonium chloride and atractylodes, wherein the weight ratio of the vitamin U to the atractylodes is 9 parts: 8 parts to 3 parts: 500 parts . For example, the gastrointestinal drug composition of claim 1 is used for the inhibition of fullness, vomiting, nausea or vomiting, or chest compression, bloating, indigestion, and stomach. Abdominal swelling or loss of appetite. For example, the gastrointestinal drug composition of claim 2, wherein the sputum, vomiting, nausea, vomiting, chest pressure, bloating, indigestion, stomach. Abdominal swelling or even loss of appetite is caused by excessive drinking or overeating. A gastrointestinal drug composition as claimed in claim 1 is for promoting digestion. The gastrointestinal drug composition according to claim 1, wherein the gastrointestinal drug composition is in the form of a powder, a granule, a lozenge, a chewable tablet, a coating agent, a sugar-coated tablet, a soft capsule or a hard capsule. .